Newly Confident Hutchmed Weans Itself from Partners, Prepares to Stand on Its Own
Oncological drug specialist backed by billionaire Li Ka-shing sells OTC business and raises $200 million, half from Baring Private Equity Asia Key Takeaways Hutchmed predicts revenue from its core oncology…
RELATED ARTICLES
-
Hutchmed scores U.S. success with cancer drug, but profits still dip
HCM.US 0013.HK -
Novel drugs lift Sino Biopharm earnings, easing price-cap pain
1177.HK
-
Innovent Bio hopes for plus-sized profits from obesity drug
1801.HK
-
CSPC Pharma taps R&D superstar in quest for new breakout drugs
1093.HK
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
Profit setback for Simcere Pharma in novel drugs quest
2096.HK
